Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Declines By 94.9%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totalling 700 shares, a drop of 94.9% from the June 15th total of 13,700 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 98,400 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Galmed Pharmaceuticals in a research note on Friday, July 5th. They issued a “sell” rating on the stock.

Galmed Pharmaceuticals Price Performance

Shares of NASDAQ GLMD remained flat at $0.30 during midday trading on Thursday. 57,293 shares of the stock were exchanged, compared to its average volume of 133,653. The stock’s 50-day simple moving average is $0.35 and its 200 day simple moving average is $0.37. The stock has a market capitalization of $1.52 million, a P/E ratio of -0.13 and a beta of 0.69. Galmed Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $5.47.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.